FDA grants Breakthrough Therapy designation to AP-SA02

Armata Pharmaceuticals received a Breakthrough Therapy designation from the FDA for AP-SA02 based on Phase 2 clinical data showing potential for substantial improvement over existing treatments for complicated S. aureus bacteremia. This adds to the company's existing regulatory designations.